Catherine Stehman-Breen is moving to Sarepta Therapeutics (NASDAQ: [[ticker:SRPT]]) to become the Cambridge, MA, company’s chief medical officer. Stehman-Breen previously served as vice president of clinical development and regulatory affairs for Regeneron Pharmaceuticals (NASDAQ: [[ticker:REGN]]), a Tarrytown, NY, biotech. Before joining Regeneron in 2015, Stehman-Breen held several posts at Amgen (NASDAQ: [[ticker:AMGN]]).
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
